

Servier Announces the appointment of a new GM of its Russian Manufacturing Complex “SERVIER RUS”

January 23rd, Moscow. – Servier, international pharmaceutical company, has announced that Christophe Wlodarczyk has been appointed the GM of “SERVIER RUS” manufacturing complex as of January 16th 2020. Christophe Wlodarczyk will be replacing Xavier Morelon, who held the position from 2017 to 2019 and is promoted at the corporate level as Servier Worldwide Supply Chain Director.

Christophe Wlodarczyk received a degree in bioprocess engineering. After working for some time in the pharmaceutical industry, in 1999 Christophe joined the Servier team as a bioprocess engineer at the Bolbec (France) production facility. In 2005 he was promoted to the position of production unit manager, and in 2015 he became GM of the Servier production facility in Brazil.

As the new GM of the Moscow-based “SERVIER RUS” manufacturing complex, Christophe Wlodarczyk will continue working on further development of the enterprise and improvement of its production efficiency, expansion of exports capabilities, development contract manufacturing as well as continue the successful implementation of serialization project. Among the priorities Christophe considers also further embodiment of environmental projects as well as Corporate Social Responsibility Initiatives integration.

Servier was among the first European companies to localize its production in Russia. Launched in 2007, the “SERVIER RUS” Pharmaceutical Plant operates in full compliance with GMP international standards, producing a broad range of modern and original medical products. Today, more than 90% of drugs in Servier Russia portfolio for the treatment of major chronic non-communicable diseases are produced in full cycle at the “SERVIER RUS” production facility. Moreover, the “SERVIER RUS” production complex also exports original medical products to EAEU countries, planning to expand exports to Central Asia and European countries.

About Servier

Servier is an international pharmaceutical Company managed by a nonprofit Fund, with its headquarters located in Suren, France. The Company operates in 149 countries across 5 continents, with some 22,000 employees. Being completely independent, the Servier Group reinvests up to 25% of its turnover in R&D (excluding generics), and all of its income in development. In 2018, Servier's annual turnover amounted to EUR 4.2 billion. The Company's fast growth rate is largely due to its constant development and search for innovative solutions in five key areas: diabetes, cardiovascular, oncological, immuno-inflammatory, and neurodegenerative diseases, as well as the creation of high-quality generic drugs. In addition to drug development, Servier offers digital healthcare solutions.

For more information: www.servier.com

About Servier in Russia

Servier has been on the Russian pharmaceutical market for more than 25 years, and is one of the country's leading pharmaceutical companies. In 1999, the Company opened a Research and Development Centre in Moscow. In 2007, a high-tech full-cycle production complex “SERVIER RUS” was launched in the Moscow suburbs, working in full compliance with the requirements of the international standard for good manufacturing practice (GMP), and producing a broad range of modern original medical products for Russian consumers. In 2012, the Company began making its first exports of drugs produced in Russia to CIS countries.

For more information, visit our website at: www.servier.ru